Andrew C Prince1, Aditi Jani1, Melissa Korb2, Kiranya E Tipirneni2, Benjamin B Kasten3, Eben L Rosenthal4, Jason M Warram5. 1. School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama. 2. Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama. 3. Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama. 4. Department of Otolaryngology, Stanford University, Stanford, California. 5. Department of Otolaryngology, University of Alabama at Birmingham, Birmingham, Alabama.
Abstract
BACKGROUND AND OBJECTIVES: Optical imaging to guide cancer resections is rapidly transitioning into the operating room. However, the sensitivity of this technique to detect subclinical disease is yet characterized. The purpose of this study was to determine the minimum range of cancer cells that can be detected by antibody-based fluorescence imaging. METHODS: 2LMP (breast), COLO-205 (colon), MiaPaca-2 (pancreas), and SCC-1 (head and neck) cells incubated in vitro with cetuximab-IRDye800CW (dose range 8.6-86 nM) were implanted subcutaneously in mice (n = 3 mice, 5 tumors/mouse). Following incubation with 8.6 × 10-2 µM of cetuximab-IRDye800CW in vitro, serial dilutions of each cell type (1 × 103 -1 × 106 ) were implanted subcutaneously (n = 3, 5 tumors/mouse). Tumors were imaged with Pearl Impulse and Xenogen IVIS 100 imaging systems. Scatchard analysis was performed to determine receptor density and kinetics for each cell line. RESULTS: Under conditions of minimal cetuximab-IRDye800CW exposure to low cellular quantity, closed-field fluorescence imaging theoretically detected a minimum of 4.2 × 104 -9.5 × 104 2LMP cells, 1.9 × 105 -4.5 × 105 MiaPaca-2 cells, and 2.4 × 104 -6.7 × 104 SCC-1 cells; COLO-205 cells could not be identified. Higher EGFR-mediated uptake of cetuximab correlated with sensitivity of detection. CONCLUSION: This study supports the clinical utility of cetuximab-IRDye800CW to sensitively localize subclinical disease in the surgical setting.
BACKGROUND AND OBJECTIVES: Optical imaging to guide cancer resections is rapidly transitioning into the operating room. However, the sensitivity of this technique to detect subclinical disease is yet characterized. The purpose of this study was to determine the minimum range of cancer cells that can be detected by antibody-based fluorescence imaging. METHODS: 2LMP (breast), COLO-205 (colon), MiaPaca-2 (pancreas), and SCC-1 (head and neck) cells incubated in vitro with cetuximab-IRDye800CW (dose range 8.6-86 nM) were implanted subcutaneously in mice (n = 3 mice, 5 tumors/mouse). Following incubation with 8.6 × 10-2 µM of cetuximab-IRDye800CW in vitro, serial dilutions of each cell type (1 × 103 -1 × 106 ) were implanted subcutaneously (n = 3, 5 tumors/mouse). Tumors were imaged with Pearl Impulse and Xenogen IVIS 100 imaging systems. Scatchard analysis was performed to determine receptor density and kinetics for each cell line. RESULTS: Under conditions of minimal cetuximab-IRDye800CW exposure to low cellular quantity, closed-field fluorescence imaging theoretically detected a minimum of 4.2 × 104 -9.5 × 104 2LMP cells, 1.9 × 105 -4.5 × 105 MiaPaca-2 cells, and 2.4 × 104 -6.7 × 104 SCC-1 cells; COLO-205 cells could not be identified. Higher EGFR-mediated uptake of cetuximab correlated with sensitivity of detection. CONCLUSION: This study supports the clinical utility of cetuximab-IRDye800CW to sensitively localize subclinical disease in the surgical setting.
Authors: Nicole M Davis; Melissa Sokolosky; Kristin Stadelman; Steve L Abrams; Massimo Libra; Saverio Candido; Ferdinando Nicoletti; Jerry Polesel; Roberta Maestro; Antonino D'Assoro; Lyudmyla Drobot; Dariusz Rakus; Agnieszka Gizak; Piotr Laidler; Joanna Dulińska-Litewka; Joerg Basecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Giuseppe Montalto; Melchiorre Cervello; Timothy L Fitzgerald; Zoya Demidenko; Alberto M Martelli; Lucio Cocco; Linda S Steelman; James A McCubrey Journal: Oncotarget Date: 2014-07-15
Authors: Eben L Rosenthal; Jason M Warram; Esther de Boer; James P Basilion; Merrill A Biel; Matthew Bogyo; Michael Bouvet; Brian E Brigman; Yolonda L Colson; Steven R DeMeester; Geoffrey C Gurtner; Takeaki Ishizawa; Paula M Jacobs; Stijn Keereweer; Joseph C Liao; Quyen T Nguyen; James M Olson; Keith D Paulsen; Dwaine Rieves; Baran D Sumer; Michael F Tweedle; Alexander L Vahrmeijer; Jamey P Weichert; Brian C Wilson; Michael R Zenn; Kurt R Zinn; Gooitzen M van Dam Journal: J Nucl Med Date: 2015-10-08 Impact factor: 10.057
Authors: Jason M Warram; Esther de Boer; Gooitzen M van Dam; Lindsay S Moore; Stephanie L Bevans; Erika M Walsh; Erik S Young; William R Carroll; Todd M Stevens; Eben L Rosenthal Journal: J Pathol Clin Res Date: 2016-03-02
Authors: Nicholas E Wojtynek; Madeline T Olson; Timothy A Bielecki; Wei An; Aaqib M Bhat; Hamid Band; Scott R Lauer; Edibaldo Silva-Lopez; Aaron M Mohs Journal: Mol Imaging Biol Date: 2020-08 Impact factor: 3.488
Authors: Andrew C Prince; Lindsay S Moore; Kiranya E Tipirneni; Tushar Ramesh; Mihir A Limdi; Stephanie L Bevans; Erika M Walsh; Benjamin Greene; Eben L Rosenthal; Jason M Warram Journal: Surg Oncol Date: 2018-04-26 Impact factor: 3.279
Authors: Thinzar M Lwin; Sophie Hernot; Hannah Hollandsworth; Siamak Amirfakhri; Filemoni Filemoni; Pieterjan Debie; Robert M Hoffman; Michael Bouvet Journal: Surgery Date: 2020-05-04 Impact factor: 3.982
Authors: Willemieke S Tummers; Jason M Warram; Nynke S van den Berg; Sarah E Miller; Rutger-Jan Swijnenburg; Alexander L Vahrmeijer; Eben L Rosenthal Journal: Theranostics Date: 2018-10-22 Impact factor: 11.556